no statement of use filed
on 13 Feb 2023
Last Applicant/ Owned by
One Amgen Center Drive
Thousand Oaks
CA
913201799
Serial Number
88329711 filed on 07th Mar 2019
Registration Number
N/A
Correspondent Address
Elsa D. Lemoine
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"BIOSIMILARS"
"BIOSIMILARS" Color is not claimed as a feature of the mark. House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceuticaRead More
House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression
No 88329711
No Service/Collective Mark
No TM-1387-US-2
No
No
No
No
No
No
No
No
09.01.04 -
Ribbons, bows
The mark consists of the stylized words "AMGEN BIOSIMILARS" positioned to the right of an interweaving double ribbon design.
Status Date | Action Taken |
---|---|
13th Feb 2023 | ABANDONMENT - NO USE STATEMENT FILED |
13th Feb 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
16th Jun 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
15th Jun 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
15th Jun 2022 | SOU EXTENSION 5 GRANTED |
07th Jun 2022 | SOU TEAS EXTENSION RECEIVED |
07th Jun 2022 | SOU EXTENSION 5 FILED |
02th Dec 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
30th Nov 2021 | SOU TEAS EXTENSION RECEIVED |
30th Nov 2021 | SOU EXTENSION 4 FILED |